DB00596 - Halobetasol Propionate
| Identification | |
|---|---|
| Name | Halobetasol Propionate |
| Accession Number | DB00596 (APRD01010) |
| Type | small molecule |
| Description | Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |
| Structure |
|
| Categories (*) | |
| Molecular Weight | 484.96 |
| Groups | approved |
| Monoisotopic Weight | 484.182808219 |
| Pharmacology | |
| Indication | For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |
| Mechanism of action | Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. |
| Absorption | The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. |
| Protein binding | Not Available |
| Biotransformation | Not Available |
| Route of elimination | Not Available |
| Toxicity | Not Available |
| Affected organisms |
|
| Interactions | |
| Drug Interactions | Not Available |
| Food Interactions | Not Available |
Targets
| Glucocorticoid receptor | |
|---|---|
| Name | Glucocorticoid receptor |
| Gene Name | NR3C1 |
| Pharmacological action | yes |
| Actions | agonist |
| References |
|
| DTHybrid score | 1.1669 |